What is the myc biomarker? Does this relate to double hit

According to the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas:

• MYC is a gene that helps control cell growth and division
• When the MYC gene becomes rearranged (moved from its normal position), it can lead to more aggressive lymphoma behavior
• MYC rearrangements are typically detected through FISH (fluorescence in situ hybridization) testing

The Leukemia & Lymphoma Society (LLS) explains that "double-hit lymphoma" refers to:

• Lymphomas that have TWO genetic rearrangements:
  1. MYC rearrangement AND
  2. Either BCL2 or BCL6 rearrangement
• This combination is now officially classified as "High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements"
• These lymphomas typically behave more aggressively and require specific treatment approaches

According to ASCO (American Society of Clinical Oncology) guidelines:

• Double-hit lymphomas generally require more intensive chemotherapy regimens than standard DLBCL
• The presence of MYC rearrangement alone or with other mutations helps doctors determine: • Prognosis • Treatment selection • Clinical trial eligibility

Always consult with your healthcare team about your specific genetic test results and what they mean for your treatment plan, as interpretation can be complex.